950130.KQ
Access Bio, Inc.
KOE · Healthcare · Medical - Diagnostics & Research · US
KRW 2,525.00
+0.60%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 23.8B | 31.3B | 112.5B | 348.6B | 1033.9B |
| Cost of Revenue | 56.7B | 55.7B | 58.8B | 178.4B | 214.1B |
| Gross Profit | (32.9B) | (24.4B) | 53.6B | 170.3B | 819.8B |
| Operating Expenses | |||||
| R&D Expense | 9.7B | 8.5B | 10.8B | 16.1B | 7.3B |
| SG&A Expense | 18.3B | 14.1B | 24.7B | 170.6B | 317.4B |
| General & Admin Expense | 2.9B | 3.6B | 5.7B | 7.1B | 5.8B |
| Selling & Marketing Expense | 5.8B | 10.5B | 19.0B | 163.5B | 311.6B |
| Other Expenses | 10.4B | 16.2B | 22.4B | (38.0B) | 25.4B |
| Total Operating Expenses | 38.5B | 38.8B | 57.9B | 148.7B | 350.2B |
| Cost and Expenses | 94.6B | 94.6B | 116.7B | 327.1B | 564.3B |
| Operating Income (EBIT) | (70.3B) | (63.4B) | (4.2B) | 21.6B | 469.2B |
| Non-Operating | |||||
| Interest Income | 14.5B | 18.2B | 14.6B | 14.4B | 5.7B |
| Interest Expense | 11.1B | 12.8B | 3.5B | 3.7B | 6.2B |
| Net Interest Income | 3.5B | 5.4B | 11.1B | 10.7B | 3.4B |
| Other Non-Op Income/Expense | (71.9B) | (42.0B) | 4.1B | (27.5B) | (5.5B) |
| Non-Operating Income (excl Interest) | 45.9B | 39.8B | (7.6B) | 23.8B | (728.3M) |
| EBT (Pre-Tax Income) | (142.4B) | (105.4B) | (143.9M) | (5.9B) | 463.7B |
| Income Tax Expense | (30.9B) | (22.3B) | 936.0M | (580.5M) | 114.0B |
| Bottom Line | |||||
| Net Income | (111.2B) | (82.1B) | (347.6M) | (3.2B) | 346.7B |
| Earnings from Cont. Ops | (112.5B) | (83.1B) | (1.1B) | (5.3B) | 349.7B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (112.2B) | (82.1B) | (347.6M) | (3.2B) | 346.7B |
| Per Share | |||||
| Basic EPS | (₩3,192) | (₩2,332) | (₩10) | (₩91) | ₩10,051 |
| Diluted EPS | (₩3,192) | (₩2,332) | (₩10) | (₩91) | ₩9,212 |
| Revenue Per Share | ₩677 | ₩889 | ₩3,202 | ₩9,999 | ₩27,473 |
| Shares | |||||
| Basic Shares Outstanding | 35.2M | 35.2M | 35.1M | 34.9M | 37.6M |
| Diluted Shares Outstanding | 35.2M | 35.2M | 35.1M | 34.9M | 37.6M |
| Profitability Metrics | |||||
| EBITDA | (102.9B) | (85.9B) | 23.4B | 13.8B | 479.1B |
| D&A | 13.4B | 17.2B | 20.1B | 16.0B | 10.8B |
| EBIT | (116.3B) | (103.1B) | 3.3B | (2.2B) | 469.9B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026